# Pomaglumetad Effects on Glutamate Biomarkers

> **NCT02919774** · PHASE1 · COMPLETED · sponsor: **New York State Psychiatric Institute** · enrollment: 95 (actual)

## Conditions studied

- Healthy Controls

## Interventions

- **DRUG:** POMA
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02919774
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2018-04-28
- **Final completion:** 2018-05-25
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2018-09-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02919774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02919774, "Pomaglumetad Effects on Glutamate Biomarkers". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02919774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*